Differential diagnosis of thymic carcinoma and lung carcinoma with the use of antibodies to cytokeratins

J Thorac Cardiovasc Surg. 1995 Dec;110(6):1670-5. doi: 10.1016/S0022-5223(95)70029-3.

Abstract

There are few specific pathologic findings that can be relied on to distinguish primary thymic carcinomas from lung carcinomas with mediastinal extension or showing metastasis to the anterior mediastinum. The immunohistochemical reactivity on frozen sections of thymic carcinomas and lung carcinomas, which are histologically similar to each other, was examined with the use of monoclonal antibodies to cytokeratins 7 and 13. Among keratinizing squamous cell carcinomas, all thymic carcinomas reacted with antibody specific for cytokeratin 7 (9/9, 0%), whereas no staining reaction was seen in lung carcinomas (0/5, 0%) (p < 0.01). This finding can be used as a diagnostic aid in primary thymic keratinizing squamous cell carcinomas to expedite treatment and prognosis. Cytokeratin 7 and cytokeratin 13 monoclonal antibodies reacted with almost all cases of thymic carcinoma. Applications of monoclonal antibodies specific for certain cytokeratins, especially 7 and 13, may be helpful in the diagnosis of other subtypes of thymic carcinomas.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal
  • Carcinoma, Squamous Cell / chemistry
  • Carcinoma, Squamous Cell / diagnosis*
  • Carcinoma, Squamous Cell / secondary
  • Diagnosis, Differential
  • Humans
  • Immunohistochemistry
  • Keratins / analysis*
  • Lung / chemistry
  • Lung / pathology
  • Lung Neoplasms / diagnosis*
  • Lung Neoplasms / pathology
  • Thymoma / chemistry
  • Thymoma / diagnosis*
  • Thymus Gland / chemistry
  • Thymus Gland / pathology
  • Thymus Neoplasms / chemistry
  • Thymus Neoplasms / diagnosis*
  • Thymus Neoplasms / secondary

Substances

  • Antibodies, Monoclonal
  • Keratins